In the December 27, 2006 issue of JAMA, the article "Effects of Continuing or Stopping Alendronate after 5 Years of Treatment" was funded by Merck who manufactures alendronate, a bisphosphonate, under the patent name Fosamax.Not only was the study supported by contracts with Merck and Co according to JAMA, it was designed jointly by the non-Merck investigators and Merck employees and written with editorial input from Merck throughout the process. The final version of the manuscript was approved by all coauthors, including Merck authors," says JAMA.
This doesn't sound like an article; it sounds like an advertorial. Who can you trust if you can't trust the Journal of American Medicine Association? (Op Ed News)
